DOJ lauds Guardant Health’s cooperation in cancer test false claims case
By 
Jeff Dale2024-07-17T20:37:00
California-based cancer testing company Guardant Health agreed to pay more than $945,000 to settle allegations levied by the Department of Justice (DOJ) of violating the False Claims Act and Stark Law.
Guardant will pay nearly $914,000 to settle allegations of the violating the False Claims Act, including more than $600,000 in restitution, according to the company’s settlement agreement. Additionally, the company will pay more than $31,000 in an administrative settlement with the Defense Health Agency, the DOJ announced in a press release Tuesday.
The DOJ acknowledged the company’s voluntary self-disclosure to the Department of Health and Human Services’ Office of the Inspector General, among other remedial measures promptly undertaken in reaching settlement.
Related articles
-
News BriefAvantor agrees to pay $5.3M to settle false claims, chemicals reporting violations
Laboratory supply company Avantor agreed to pay $5.3 million to settle allegations, first brought by a whistleblower, that it overcharged four federal agencies and failed to comply with chemical regulations, the Department of Justice said.
-
News BriefKindred hospice agrees to pay $19M in multi-state DOJ false claims case
A multi-state hospice home health provider agreed to pay $19.4 million to settle allegations that it paid kickbacks and knowingly billed federal health programs to treat non-terminally ill patients.
-
PremiumCompliance survey shows clawback policies and cooperation tools largely unused
Many companies have strong compliance policies to encourage cooperation with regulators and hold staff accountable, but these policies are rarely used, and cooperation often depends on cost and business benefit, according to a new survey of compliance professionals.
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”